The GUARD-AF trial promotes heightened knowledge of stroke risk among patients with atrial fibrillation by analyzing, evaluating, and distributing important data back to practitioners, which can possibly reduce the incidence of stroke, said Roland Chen, MD, MS, vice president and head of clinical development for innovative medicines at Bristol-Myers Squibb.
The GUARD-AF trial promotes heightened knowledge of stroke risk among patients with atrial fibrillation by analyzing, evaluating, and distributing important data back to practitioners, which can possibly reduce the incidence of stroke, said Roland Chen, MD, MS, vice president and head of clinical development for innovative medicines at Bristol-Myers Squibb.
Transcript
Can you discuss the implementation of the GUARD-AF trial and why a study focusing on preventive measures associated with the likelihood of related adverse outcomes (e.g. stroke) is warranted?
GUARD-AF is a potentially practice informing study that could help change the way in which medicine is practiced in reducing stroke in patients with atrial fibrillation (AF). AF is a condition with a high unmet need. It's estimated that about 8 million people in the United States have atrial fibrillation; but importantly, many people are not aware that they have atrial fibrillation. Many people find that stroke is the first sign of their atrial fibrillation, and strokes in people with AF are severe. In about 25% of individuals, they will die prematurely in the first 30 days after a stroke. However, there haven't been any studies that have demonstrated that screening for AF actually reduces the risk of stroke versus usual care. So, GUARD-AF is a study that will provide important information on that question.
Maybe I could take a few moments to describe the GUARD-AF study. GUARD-AF is a study that compares screening for atrial fibrillation versus standard of care. It'll randomize 52,000 patients over 300 US primary care centers—these will be patients who are on Medicare. Now patients who are randomized to receive screening will administer a patch for 14 days which will collect information on their heart rhythm. This data will be analyzed, evaluated, and fed back to the practitioner. The practitioner can then make an informed judgment on how best to treat that patient moving forward. So, GUARD-AF will hopefully provide important information on whether that intervention, that is screening for stroke or screening for atrial fibrillation, will actually reduce the incidence of stroke.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More